Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H1 2018
Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H1 2018
SUMMARY
Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 20 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H1 2018, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Transforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF-?1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts.
It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.
The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 8 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Gastrointestinal, Immunology, Ophthalmology, Respiratory, Central Nervous System, Genetic Disorders, Hematological Disorders and Metabolic Disorders which include indications Fibrosis, Kidney Fibrosis, Liver Fibrosis, Myelofibrosis, Osteoarthritis, Acute Pain, Anemia, Atherosclerosis, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Cervical Cancer, Chronic Pancreatitis Pain, Diabetic Nephropathy, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hypertrophic Scars, Idiopathic Pulmonary Fibrosis, Inflammation, Lung Adenocarcinoma, Metastatic Breast Cancer, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Open-Angle Glaucoma, Osteogenesis Imperfecta, Peripheral Artery Occlusive Disease (PAOD), Primary Sclerosing Cholangitis, Proliferative Vitreoretinopathy (PVR), Pulmonary Fibrosis, Pulmonary Hypertension, Scar, Skin Inflammation, Solid Tumor, Squamous Cell Carcinoma, Systemic Sclerosis (Scleroderma) and Wounds.
Furthermore, this report also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects.
Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 20 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H1 2018, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Transforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF-?1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts.
It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.
The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 8 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Gastrointestinal, Immunology, Ophthalmology, Respiratory, Central Nervous System, Genetic Disorders, Hematological Disorders and Metabolic Disorders which include indications Fibrosis, Kidney Fibrosis, Liver Fibrosis, Myelofibrosis, Osteoarthritis, Acute Pain, Anemia, Atherosclerosis, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Cervical Cancer, Chronic Pancreatitis Pain, Diabetic Nephropathy, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hypertrophic Scars, Idiopathic Pulmonary Fibrosis, Inflammation, Lung Adenocarcinoma, Metastatic Breast Cancer, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Open-Angle Glaucoma, Osteogenesis Imperfecta, Peripheral Artery Occlusive Disease (PAOD), Primary Sclerosing Cholangitis, Proliferative Vitreoretinopathy (PVR), Pulmonary Fibrosis, Pulmonary Hypertension, Scar, Skin Inflammation, Solid Tumor, Squamous Cell Carcinoma, Systemic Sclerosis (Scleroderma) and Wounds.
Furthermore, this report also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects.
Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)
- The report reviews Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Transforming Growth Factor Beta 1 (TGFB1) - Overview
Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transforming Growth Factor Beta 1 (TGFB1) - Companies Involved in Therapeutics Development
Acceleron Pharma Inc
AlfaSigma SpA
Ensol Biosciences Inc
Formation Biologics Inc
Genzyme Corp
Huabo Biopharm Co Ltd
Isarna Therapeutics GmbH
Johnson & Johnson
Novartis AG
Scholar Rock Inc
Sirnaomics Inc
Transforming Growth Factor Beta 1 (TGFB1) - Drug Profiles
ACE-1332 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVID-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
decorin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Engedi-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluorofenidone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fresolimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-1047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-1106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melittin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit TGF Beta1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody 1 to Inhibit TGFB1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TGFB1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TGFB1 for Oncology and Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Inhibit TGF Beta 1 for Squamous Cell Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-705 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sulodexide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XOMA-089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Transforming Growth Factor Beta 1 (TGFB1) - Dormant Products
Transforming Growth Factor Beta 1 (TGFB1) - Discontinued Products
Transforming Growth Factor Beta 1 (TGFB1) - Product Development Milestones
Featured News & Press Releases
Feb 17, 2018: AVID200 Program Featured in an Oral Presentation at the 5th Systemic Sclerosis World Congress and Received an Award for One of the Most Original Works Presented at the Congress
Feb 02, 2018: Formation Biologics Announces Award of $675,000 BioCanRx Grant to Support Development of AVID200
Dec 06, 2017: Sirnaomics' Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for Treatment of Cholangiocarcinoma
Oct 06, 2017: Sirnaomics Publishes Results Showing Dual Targeting of TGF-?1 and COX-2 Reduces Human Skin Hypertrophic Scar through Activation of Fibroblast Apoptosis
Aug 01, 2017: Sirnaomics Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for the Treatment of Primary Sclerosing Cholangitis
Jun 15, 2017: Sirnaomics Advances Leading siRNA Therapeutic Candidate, STP705, for Treatment of Liver Fibrosis
May 01, 2017: Sirnaomics Received IND Approval from CFDA for Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar
Feb 06, 2017: Sirnaomics Initiates a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar
Jan 03, 2017: Haiyao Obtains Clinical Trial Approval for Fluorofenidone from General Administration of Pharmacy, China
Nov 07, 2016: Sirnaomics Received Green Light from US FDA for a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar
Jul 14, 2015: Scholar Rock Presents Preclinical Data for First Demonstration of Novel Pharmacological Approach to Targeting the TGF?1 Latent Complex
Jan 22, 2015: Sirnaomics Files to Begin Trial of Scar-healing Drug in China as it Seeks Funding in US
Jan 05, 2015: Sirnaomics and Partner Submit IND to CFDA
Jun 28, 2012: Sirnaomics Nears Phase I Study of Wound-Healing Drug as It Eyes the microRNA Field
Jun 25, 2012: Sirnaomics Receives NIH SBIR Grant For Developing siRNA Therapeutic Product STP705
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Transforming Growth Factor Beta 1 (TGFB1) - Overview
Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transforming Growth Factor Beta 1 (TGFB1) - Companies Involved in Therapeutics Development
Acceleron Pharma Inc
AlfaSigma SpA
Ensol Biosciences Inc
Formation Biologics Inc
Genzyme Corp
Huabo Biopharm Co Ltd
Isarna Therapeutics GmbH
Johnson & Johnson
Novartis AG
Scholar Rock Inc
Sirnaomics Inc
Transforming Growth Factor Beta 1 (TGFB1) - Drug Profiles
ACE-1332 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVID-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
decorin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Engedi-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluorofenidone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fresolimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-1047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-1106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melittin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit TGF Beta1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody 1 to Inhibit TGFB1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TGFB1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TGFB1 for Oncology and Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Inhibit TGF Beta 1 for Squamous Cell Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-705 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sulodexide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XOMA-089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Transforming Growth Factor Beta 1 (TGFB1) - Dormant Products
Transforming Growth Factor Beta 1 (TGFB1) - Discontinued Products
Transforming Growth Factor Beta 1 (TGFB1) - Product Development Milestones
Featured News & Press Releases
Feb 17, 2018: AVID200 Program Featured in an Oral Presentation at the 5th Systemic Sclerosis World Congress and Received an Award for One of the Most Original Works Presented at the Congress
Feb 02, 2018: Formation Biologics Announces Award of $675,000 BioCanRx Grant to Support Development of AVID200
Dec 06, 2017: Sirnaomics' Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for Treatment of Cholangiocarcinoma
Oct 06, 2017: Sirnaomics Publishes Results Showing Dual Targeting of TGF-?1 and COX-2 Reduces Human Skin Hypertrophic Scar through Activation of Fibroblast Apoptosis
Aug 01, 2017: Sirnaomics Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for the Treatment of Primary Sclerosing Cholangitis
Jun 15, 2017: Sirnaomics Advances Leading siRNA Therapeutic Candidate, STP705, for Treatment of Liver Fibrosis
May 01, 2017: Sirnaomics Received IND Approval from CFDA for Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar
Feb 06, 2017: Sirnaomics Initiates a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar
Jan 03, 2017: Haiyao Obtains Clinical Trial Approval for Fluorofenidone from General Administration of Pharmacy, China
Nov 07, 2016: Sirnaomics Received Green Light from US FDA for a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar
Jul 14, 2015: Scholar Rock Presents Preclinical Data for First Demonstration of Novel Pharmacological Approach to Targeting the TGF?1 Latent Complex
Jan 22, 2015: Sirnaomics Files to Begin Trial of Scar-healing Drug in China as it Seeks Funding in US
Jan 05, 2015: Sirnaomics and Partner Submit IND to CFDA
Jun 28, 2012: Sirnaomics Nears Phase I Study of Wound-Healing Drug as It Eyes the microRNA Field
Jun 25, 2012: Sirnaomics Receives NIH SBIR Grant For Developing siRNA Therapeutic Product STP705
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Acceleron Pharma Inc, H1 2018
Pipeline by AlfaSigma SpA, H1 2018
Pipeline by Ensol Biosciences Inc, H1 2018
Pipeline by Formation Biologics Inc, H1 2018
Pipeline by Genzyme Corp, H1 2018
Pipeline by Huabo Biopharm Co Ltd, H1 2018
Pipeline by Isarna Therapeutics GmbH, H1 2018
Pipeline by Johnson & Johnson, H1 2018
Pipeline by Novartis AG, H1 2018
Pipeline by Scholar Rock Inc, H1 2018
Pipeline by Sirnaomics Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Acceleron Pharma Inc, H1 2018
Pipeline by AlfaSigma SpA, H1 2018
Pipeline by Ensol Biosciences Inc, H1 2018
Pipeline by Formation Biologics Inc, H1 2018
Pipeline by Genzyme Corp, H1 2018
Pipeline by Huabo Biopharm Co Ltd, H1 2018
Pipeline by Isarna Therapeutics GmbH, H1 2018
Pipeline by Johnson & Johnson, H1 2018
Pipeline by Novartis AG, H1 2018
Pipeline by Scholar Rock Inc, H1 2018
Pipeline by Sirnaomics Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Acceleron Pharma Inc
AlfaSigma SpA
Ensol Biosciences Inc
Formation Biologics Inc
Genzyme Corp
Huabo Biopharm Co Ltd
Isarna Therapeutics GmbH
Johnson & Johnson
Novartis AG
Scholar Rock Inc
Sirnaomics Inc
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Acceleron Pharma Inc
AlfaSigma SpA
Ensol Biosciences Inc
Formation Biologics Inc
Genzyme Corp
Huabo Biopharm Co Ltd
Isarna Therapeutics GmbH
Johnson & Johnson
Novartis AG
Scholar Rock Inc
Sirnaomics Inc
